Statins and blood pressure regulation

被引：44

作者：

Borghi C. ^{[1
]}

Veronesi M. ^{[1
]}

Prandin M.G. ^{[1
]}

Dormi A. ^{[1
]}

Ambrosioni E. ^{[1
]}

机构：

[1] Divisione di Medicina Interna, Policlinico S. Orsola, 40138 Bologna

来源：

Current Hypertension Reports | 2001年 / 3卷 / 4期

关键词：

Simvastatin; Pravastatin; Lovastatin; Blood Pressure Control; Blood Pressure Regulation;

D O I：

10.1007/s11906-001-0090-y

中图分类号：

学科分类号：

摘要：

Hypertension and high serum cholesterol levels are two of the most relevant risk factors for cardiovascular diseases. A combined increase in both risk factors has been reported in a significant proportion of patients with coronary artery disease. Statins are the most widely used drugs to treat hypercholesterolemia, and they interact with blood pressure control in different populations of hypertensive patients. A significant reduction in blood pressure associated with the use of statins has been described in patients with untreated hypertension and in patients treated with antihypertensive drugs, particularly angiotensin converting enzyme inhibitors and calcium channel blockers. The effect of statins on blood pressure control has also been reported in diabetic patients. The mechanisms responsible for the hypotensive effect seem to be largely independent of the effect of statins on lipid profile, and are probably related to their interaction with endothelial function or angiotensin II receptors. The capacity of statins to improve blood pressure control could be a useful consideration for an integrated approach to better prevention of cardiovascular diseases. Copyright © 2001 by Current Science Inc.

引用

页码：281 / 288

页数：7

共 45 条

[41] Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W., Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions, J Am Coll Cardiol, 33, pp. 234-241, (1999)
[42] Nickenig G., Baumer A.T., Temur Y., Et al., Statin-sensitive dysreg-ulated AT1 receptor function and density in hypercholesterolemic men, Circulation, 100, pp. 2131-2134, (1999)
[43] Ide H., Fujiya S., Aanuma Y., Et al., Effects of simvastatin, an HMG-coa reductase inhibitor, on plasma lipids and steroid hormones, Clin Ther, 12, 5, pp. 410-420, (1990)
[44] Sartor G., Katzman P., Eizyk E., Et al., Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus, Int J Clin Pharmacol Ther, 33, pp. 3-6, (1995)
[45] Nazzaro P., Manzari M., Merlo M., Et al., Distinct and combined vascular effects of ACE blockade and HMG-coa reductase inhibition in hypertensive subjects, Hypertension, 33, pp. 719-725, (1999)

← 1 2 3 4 5 →